Filing Details
- Accession Number:
- 0001104659-20-090470
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2020-08-04 21:02:27
- Reporting Period:
- 2020-08-03
- Accepted Time:
- 2020-08-04 21:02:27
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1621227 | Adaptimmune Therapeutics Plc | ADAP | Biological Products, (No Disgnostic Substances) (2836) | 000000000 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1784487 | John Lunger | C/O Adaptimmune Therapeutics Plc, 60 Jubilee Avenue, Milton Park Abingdon X0 OX14 4RX | Chief Patient Supply Officer | No | Yes | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
American Depositary Shares Representing Ordinary Shares | Disposition | 2020-08-03 | 4,823 | $9.25 | 8,066 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | S | Direct |
Footnotes
- Each American Depositary Share ("ADS") represents six ordinary shares, nominal value GBP 0.001 per ordinary share, of the Issuer. The ADSs were obtained from the exercise of approximately 25% of an RSU-style share option covering ordinary shares of the Issuer granted on July 2, 2018 and which vested on July 2, 2020 and from the exercise of approximately 25% of an RSU-style share option covering ordinary shares of the Issuer granted on August 1, 2019 and which vested on August 1, 2020. Once vested, the RSU-style options must be exercised within a restricted period or they are forfeited.
- The exercise of the portion of these RSU-style share options and the sale reported in this Form 4 were effected pursuant to a Sell to Cover exercise implemented automatically in accordance with the Issuer's option plan, under which sufficient ADSs were sold by the Issuer to satisfy the Reporting Person's tax withholding obligations and associated sale costs. The residual ADSs are held by the Reporting Person.
- These ADSs were sold in multiple transactions at a price of $9.25. Upon request, the Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission with full information regarding the ADSs sold at this price in this footnote.
- The ADSs reported in this Column 5 represent solely those residual ADSs held by the Reporting Person which result from the Sell to Cover exercise transaction reported on this Form 4. Additionally, the Reporting Person holds 8,159 ADSs and RSU-style options and other options covering an aggregate of 3,598,014 ordinary shares of the Issuer.